The success of copyright’s blockbuster initially sparked a period of growth for pharma, but recent changes present a complicated picture for shareholders. Lower-cost competitors are reducing earnings, and persistent litigation add further risk to the landscape. While some companies may still see gains from complementary products, the broader tren